<a href="https://laohu8.com/S/GRCE">Grace Therapeutics</a> reports decreased net loss for second quarter 2026
Grace Therapeutics Inc. reported a net loss of $0.9 million for the three months ended September 30, 2025, a decrease of $2.5 million from a net loss of $3.4 million for the same period in 2024. Research and development expenses were $0.6 million, down from $3.0 million, mainly due to the completion of the GTx-104 pivotal Phase 3 STRIVE-ON safety trial. General and administrative expenses increased slightly to $2.0 million from $1.9 million, primarily due to pre-commercial planning costs for GTx-104. Cash and cash equivalents as of September 30, 2025, were $16.9 million, a decrease of $5.2 million from March 31, 2025. In October 2025, the company received $4.0 million from exercises of common warrants. Key business developments included FDA acceptance for review of the New Drug Application for GTx-104, with a PDUFA target date set for April 23, 2026, and the presentation of Phase 3 STRIVE-ON trial data.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grace Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-25-041807), on November 13, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.